Chromocell to Present at Upcoming Fall Investor Conferences
Chromocell Therapeutics (NYSE American: CHRO), a non-opioid pain treatment developer, has announced its participation in two upcoming investor conferences. CEO Frank Knuettel II will present at the LDMicro Main Event XVII on October 29, 2024, from 10:00-10:25 AM PT in Los Angeles, and at the Spartan Capital Investor Conference on November 4, 2024, from 9:45-10:00 AM ET in NYC.
Both events offer opportunities for one-on-one meetings and networking with institutional investors, industry leaders, and capital market representatives. The LDMicro event focuses on showcasing emerging micro-cap companies, while the Spartan conference brings together public company executives and institutional investors for strategic discussions.
Chromocell Therapeutics (NYSE American: CHRO), un'azienda che sviluppa trattamenti per il dolore non oppioidi, ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'amministratore delegato Frank Knuettel II presenterà all'LDMicro Main Event XVII il 29 ottobre 2024, dalle 10:00 alle 10:25 AM PT a Los Angeles, e alla Spartan Capital Investor Conference il 4 novembre 2024, dalle 9:45 alle 10:00 AM ET a New York.
Entrambi gli eventi offrono opportunità per incontri one-on-one e networking con investitori istituzionali, leader di settore e rappresentanti dei mercati finanziari. L'evento LDMicro si concentra sulla presentazione di aziende emergenti a bassa capitalizzazione, mentre la conferenza Spartan riunisce dirigenti di aziende pubbliche e investitori istituzionali per discussioni strategiche.
Chromocell Therapeutics (NYSE American: CHRO), un desarrollador de tratamientos para el dolor no opioide, ha anunciado su participación en dos próximas conferencias para inversores. El CEO Frank Knuettel II presentará en el LDMicro Main Event XVII el 29 de octubre de 2024, de 10:00 a 10:25 AM PT en Los Ángeles, y en la Spartan Capital Investor Conference el 4 de noviembre de 2024, de 9:45 a 10:00 AM ET en Nueva York.
Ambos eventos ofrecen oportunidades para reuniones uno a uno y redes de contacto con inversores institucionales, líderes de la industria y representantes del mercado de capitales. El evento LDMicro se centra en mostrar empresas emergentes de pequeña capitalización, mientras que la conferencia Spartan reúne a ejecutivos de empresas públicas e inversores institucionales para discusiones estratégicas.
Chromocell Therapeutics (NYSE American: CHRO)는 비오피오이드 통증 치료제를 개발하는 기업으로, 두 개의 다가오는 투자자 컨퍼런스에 참여한다고 발표했습니다. CEO Frank Knuettel II는 2024년 10월 29일 오전 10시부터 10시 25분까지 PT에 로스앤젤레스에서 열리는 LDMicro Main Event XVII에서 발표하며, 2024년 11월 4일 오전 9시 45분부터 10시까지 ET에 뉴욕에서 열리는 Spartan Capital Investor Conference에서도 발표할 예정입니다.
두 행사 모두 기관 투자자, 업계 리더 및 자본 시장 대표와의 일대일 회의 및 네트워킹 기회를 제공합니다. LDMicro 이벤트는 신흥 마이크로캡 기업을 소개하는 데 중점을 두고 있으며, Spartan 컨퍼런스는 공기업 운영자와 기관 투자자를 모아 전략적 논의를 진행합니다.
Chromocell Therapeutics (NYSE American: CHRO), un développeur de traitements antidouleur non opioïdes, a annoncé sa participation à deux prochaines conférences pour investisseurs. Le PDG Frank Knuettel II présentera lors de l'LDMicro Main Event XVII le 29 octobre 2024, de 10h00 à 10h25 PT à Los Angeles, et lors de la Spartan Capital Investor Conference le 4 novembre 2024, de 9h45 à 10h00 ET à New York.
Ces deux événements offrent des opportunités de réunions individuelles et de réseautage avec des investisseurs institutionnels, des leaders de l'industrie et des représentants des marchés de capitaux. L'événement LDMicro met l'accent sur la mise en avant d'entreprises émergentes de petite capitalisation, tandis que la conférence Spartan réunit des dirigeants d'entreprises publiques et des investisseurs institutionnels pour des discussions stratégiques.
Chromocell Therapeutics (NYSE American: CHRO), ein Entwickler von nicht-opioiden Schmerzbehandlungen, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. CEO Frank Knuettel II wird am 29. Oktober 2024 von 10:00 bis 10:25 Uhr PT in Los Angeles beim LDMicro Main Event XVII präsentieren und am 4. November 2024 von 9:45 bis 10:00 Uhr ET in New York beim Spartan Capital Investor Conference.
Beide Veranstaltungen bieten Möglichkeiten für persönliche Treffen und Networking mit institutionellen Investoren, Branchenführern und Vertretern der Kapitalmärkte. Die LDMicro-Veranstaltung konzentriert sich auf die Präsentation aufstrebender Mikro-Kapitalunternehmen, während die Spartan-Konferenz Führungskräfte öffentlicher Unternehmen und institutionelle Investoren für strategische Diskussionen zusammenbringt.
- None.
- None.
FREEHOLD, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that Frank Knuettel II, CEO, will present at the upcoming LDMicro and Spartan Capital investor conferences.
Details for the conferences and presentations are as follows:
LDMicro Main Event XVII (October 28-30, 2024)
Presentation: October 29, 2024
Time: 10:00 AM - 10:25 AM PT
Location: Luxe Sunset BLVD Hotel, Los Angeles
In-person registration: LINK
Virtual attendance: LINK
Available for 1x1 meetings: October 29th
The Main Event has become the industry standard for anyone who is involved in the micro-cap world. Come join us as we showcase the next “big” names in our space. LD Micro Main Event XVII (October 29th & 30th)
Spartan Capital Investor Conference 2024 (November 4, 2024)
Presentation: November 4, 2024
Time: 9:45 AM - 10:00 AM ET
Location: The Pierre Hotel, NYC
Register for In-person attendance: LINK
Available for 1x1 meetings.
The Spartan Capital Investor Conference is a premier event that brings together public company executive teams, institutional investors, thought leaders in the U.S. capital markets, and representatives from Spartan Capital. This conference offers a unique opportunity for networking, knowledge sharing, and strategic discussions. The conference attracts a distinguished audience, including executive teams from public companies, institutional investors, thought leaders in the U.S. capital markets, Spartan Capital representatives.
About Chromocell
Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and acute and chronic eye pain. For company updates and to learn more about Chromocell, visit www.chromocell.com or follow us on social media.
Forward-Looking Statements
This press release contains forward-looking statements regarding the Company’s current expectations. These forward-looking statements include, without limitation, references to the Company’s expectations regarding (i) the amount of shares of Common Stock to be repurchased under the Repurchase Plan, if any, (ii) the Company’s belief that the trading price of its Common Stock does not reflect its clinical progress, (iii) the Company’s plans and ability to successfully develop and commercialize compounds, (iv) the Company’s belief that its portfolio of therapeutics will be suitable for neuropathic and chronic pain, (v) the Company’s plan and ability to successfully develop its intellectual properly independently or with partners, (vi) the Company’s ability to conduct repurchases in accordance with applicable laws and regulations, (vii) our ability to enhance stockholder value and (viii) the impact of laws and regulations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict.
Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to (i) the Company expending its limited resources to pursue a compound or indication and failing to capitalize on different compounds or indications that may be more profitable or for which there is a greater likelihood of success and the Company potentially not being successful in discovering, developing and commercializing additional compounds, (ii) the Company needing to establish its market development capabilities to commercialize its products with the failure to do so potentially resulting in an inability to generate any revenue, (iii) there being no guarantee that the trading price of the Company’s Common Stock will be indicative of the Company’s clinical progress, and (iv) the Company’s ability to successfully develop its intellectual property and portfolio. These and other risks and uncertainties are described more fully in in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
FAQ
When will Chromocell (CHRO) present at the LDMicro Main Event XVII?
What time is Chromocell's (CHRO) presentation at the Spartan Capital Conference 2024?
Which investor conferences will Chromocell (CHRO) attend in Fall 2024?
Who will represent Chromocell (CHRO) at the Fall 2024 investor conferences?
